Krystal Biotech, Inc. $KRYS Shares Bought by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund boosted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 15.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,245 shares of the company’s stock after acquiring an additional 1,934 shares during the period. Illinois Municipal Retirement Fund’s holdings in Krystal Biotech were worth $2,515,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of KRYS. Profund Advisors LLC grew its holdings in shares of Krystal Biotech by 2.0% during the third quarter. Profund Advisors LLC now owns 8,330 shares of the company’s stock valued at $1,470,000 after purchasing an additional 164 shares during the last quarter. Oppenheimer Asset Management Inc. acquired a new position in shares of Krystal Biotech during the third quarter valued at $223,000. Smartleaf Asset Management LLC raised its stake in shares of Krystal Biotech by 101.0% during the third quarter. Smartleaf Asset Management LLC now owns 422 shares of the company’s stock valued at $75,000 after purchasing an additional 212 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Krystal Biotech by 106.9% in the third quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares during the period. Finally, Optimize Financial Inc bought a new position in Krystal Biotech in the 3rd quarter valued at about $497,000. 86.29% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider owned 1,413,711 shares in the company, valued at approximately $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 12,500 shares of the stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at $5,257,200.52. This trade represents a 39.29% decrease in their position. The SEC filing for this sale provides additional information. 13.70% of the stock is owned by corporate insiders.

Krystal Biotech Stock Performance

Shares of KRYS opened at $276.45 on Monday. The firm has a market cap of $8.02 billion, a PE ratio of 41.45 and a beta of 0.49. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $295.98. The business’s 50 day moving average price is $262.06 and its two-hundred day moving average price is $206.09.

Analysts Set New Price Targets

A number of analysts have recently weighed in on KRYS shares. The Goldman Sachs Group upped their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research report on Friday, January 9th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $310.00 price objective (up previously from $240.00) on shares of Krystal Biotech in a research note on Friday, January 9th. Finally, Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Krystal Biotech presently has a consensus rating of “Moderate Buy” and a consensus price target of $277.89.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.